Hylenex may have role in analgesia, says trial

Biopharmaceutical firm Halozyme Therapeutics and fellow USA-based group Baxter Healthcare say that data from a Phase IIIb trial, in which the co-developed agent Hylenex (recombinant human hyaluronidase) is administered via subcutaneous injection in combination with morphine, show that the treatment accelerates the time to maximal blood morphine levels by 33%.

In addition, the study shows that subcutaneous administration of Hylenex and morphine provided comparable levels of drug exposure to those achieved using an intravenous delivery method.

Approach may improve analgesia